MO - Altria Group, Inc.

NYSE - NYSE Delayed Price. Currency in USD
+0.22 (+0.47%)
At close: 4:04PM EDT

46.79 +0.09 (0.19%)
After hours: 7:16PM EDT

Stock chart is not supported by your current browser
Previous Close46.48
Bid46.75 x 1300
Ask46.98 x 900
Day's Range46.64 - 47.19
52 Week Range42.40 - 66.04
Avg. Volume7,674,163
Market Cap87.24B
Beta (3Y Monthly)0.35
PE Ratio (TTM)13.94
EPS (TTM)3.35
Earnings DateOct 31, 2019
Forward Dividend & Yield3.20 (6.88%)
Ex-Dividend Date2019-06-13
1y Target Est57.67
Trade prices are not sourced from all markets
  • What Kind Of Shareholder Appears On The Altria Group, Inc.'s (NYSE:MO) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Altria Group, Inc.'s (NYSE:MO) Shareholder Register?

    Every investor in Altria Group, Inc. (NYSE:MO) should be aware of the most powerful shareholder groups. Institutions...

  • InvestorPlace

    Why I’m Still Bullish on Canopy Growth Stock for the Cannabis Long Term

    There's no sugarcoating the truth here. It has been an awful few weeks for pot stocks, particularly the cannabis market leader, Canopy Growth (NYSE:CGC). At the end of April, CGC stock was flying high above $50 - up 90% year-to-date, as investors were getting excited about Canopy's potential entry into the what-will-be-huge U.S. cannabis market. Two bad earnings reports later, the stock has come crashing down.Source: Shutterstock Today, CGC stock trades hands below $30 - nearly 50% off its late April highs, and up just 5% year-to-date, versus a 90% year-to-date gain back in April.If that's not a crash, I don't know what is. Indeed, the crash has been so bad that some bulls have thrown in the towel.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI get it. Stomaching a 50% crash over four months is not an easy thing to do. It does leave one feeling somewhat hopeless, dejected, and unwilling to double down.But, that's exactly what I'm doing here -- doubling down. Investors have to see the forest for the trees here. All this near-term volatility is just noise. Who really cares if Canopy grew sales by 200% or 250% last quarter? Or if gross margins were 20% or 25%? All that really matters is that Canopy continues to position itself as the profitable leader in what will one day be a multi-hundred billion dollar global cannabis market.Canopy is doing just that, and because they are, there is still visibility for Canopy to one day be a $50 to 100 billion company. CGC stock has a market cap of under $10 billion today. Thus, the long-term investment implication is simple: buy on weakness and hold for the long haul. Early Innings for Pot's Global GrowthWhen it comes to CGC stock, investors need to see the big picture here and if they don't want to do that, they probably shouldn't even be looking at the cannabis space at all. * 10 Stocks Under $5 to Buy for Fall The big picture here is that you have a cannabis industry that is in the top of the first inning of a multi-year, global growth narrative. Only one major developed economy has fully legalized cannabis (Canada), where it has been fully legal for less than a year, and that economy is considered one of the smaller fish in the global market. Judging the long-term fate of a cannabis company because they missed sales or earnings estimates last quarter seems … foolish.Doing so would be focusing on a tree. Instead, investors need to take a step back, and look at the forest. Here's what the cannabis forest looks like. There is an overwhelming amount of data out there which implies that cannabis consumption is: on a secular uptrend; nearly as pervasive as alcohol and tobacco consumption; and, in many instances, preferred to alcohol consumption among younger consumers.At the same time, governments around the world are becoming open to consideration of cannabis as a "safe drug" and are gradually progressing toward full legalization. Combining those two observations, the implication is clear: the global cannabis market will be fully legal one day, and when that happens, it will be huge -- like global alcohol and tobacco markets huge. Canopy Growth Stock Still Projects as a Long-Term WinnerThe global alcohol and tobacco markets are several hundred billion dollar to trillion dollar markets. The cannabis market will be that big one day.Each of those markets has also produced several $50 billion to $100 billion-plus companies. See Anheuser-Busch (NYSE:BUD), Diageo (NYSE:DEO), or Heineken (OTCQX:HEINY) in the alcohol world. See Altria (NYSE:MO) and Philip Morris (NYSE:PM) in the tobacco world.The cannabis market will similarly produce several $50 to $100 billion-plus companies at scale. Canopy Growth will be one of them.Even the company's former CEO, Bruce Linton, unceremoniously booted out last month as Canopy's co-CEO and board chair, told BNN Bloomberg he was a buyer of CGC stock after the shares fell on August 15.Right now, Canopy is the biggest cannabis company in the fully legal Canadian market. It also has the largest balance sheet, with the most cash firepower to increase production capacity, expand global distribution, penetrate other cannabis markets, and invest in next-gen product R&D -- overall, sustaining and expanding its leadership position.Canopy is doing all of those things. The company's harvest amounted to more than 40,000 kilograms last quarter -- no one else in this space even comes close to touching that number. Canopy has a deal to acquire Acreage once the U.S. market becomes fully legal, giving the company a clear pathway to penetrating the U.S. market. They also poured over C$8 billion into R&D last quarter. Competitor Tilray (NASDAQ:TLRY) spent less than $2 billion CAD ($1.5 billion) on R&D in the overlapping quarter.In other words, Canopy is doing everything it needs to do in order to be the Anheuser-Bush or Altria of the cannabis world. Big picture, that means CGC stock remains on track to have a $50 billion to $100 billion-plus market cap one day. The market cap today? Under $10 billion. For long-term investors who are willing to ride out the volatility, the implication is clear: buy on weakness and hold for the long haul. Bottom Line on CGC StockWhen it comes to CGC stock, investors need to see the forest for the trees.True, it has a caretaker CEO after Linton fell out with shareholder Constellation Brands (NYSE:STZ), but there are indications that Canopy is looking at candidates from the consumer, pharmaceutical, alcohol and even technology sectors, according to BNN Bloomberg. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond But put that aside for a minute. As well, forget today's depressed gross margins. They are depressed because Canopy is spending an arm and a leg to lay the foundation for long-term growth. Forget today's slowing growth trends. Growth is slowing because Canopy is more focused on maximizing long-term growth, not supercharging near-term improvements.Instead, understand that Canopy is laying the groundwork to become a $50 billion to $100 billion-plus company one day.I get that it's tough to do that on the heels of a 50% sell-off over the past four months. But, CGC stock is still up 5% since January 2019, 20% since January 2018, and 300% since January 2017. So, again, the best thing here is to zoom out and contextualize everything.When you do that, it becomes clear that Canopy is still a winning company, and that CGC stock still has tremendous long term potential.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post Why I'm Still Bullish on Canopy Growth Stock for the Cannabis Long Term appeared first on InvestorPlace.

  • Reuters

    UPDATE 2-Juul raises $325 million in equity and debt financing for global expansion

    U.S. e-cigarette maker Juul Labs Inc has raised $325 million in an equity and debt offering to speed up its global reach at a time of intense regulatory scrutiny in its home market. The company did not break out the ratio of equity and debt offered, but a source familiar with the matter told Reuters that Juul sold convertible debt in a bridge financing to bolster its balance sheet. Juul, 35% owned by Marlboro maker Altria Group Inc, has over the past year focused its efforts on growing outside the United States, as American regulators increase oversight of e-cigarette products that are wildly popular among teenagers.

  • Financial Times

    Juul raises $325m in fresh funding

    Juul Labs, the US ecigarette start-up, has raised $325m in fresh funding as it plans international expansion and faces growing scrutiny from politicians and regulators at home. The cash was raised through a bridge financing structured as a convertible note, said three people familiar with the deal, a form of debt that start-ups sometimes use to raise money between equity sales. Tiger Global Management, which led an investment valuing the company at $15bn last July, participated in the new debt offering, one of the people familiar with the transaction said.

  • Better Buy: Aurora Cannabis vs. Cronos Group
    Motley Fool

    Better Buy: Aurora Cannabis vs. Cronos Group

    They're two of the most-followed cannabis stocks on the market. But which is the better pick for long-term investors?

  • InvestorPlace

    Is Hexo Stock a Falling Knife Or Has It Reached a Good Entry Point?

    The recent market drop has certainly been brutal and quite broad. But then again, this bear move is opening up interesting opportunities.Just look at the cannabis space. In fact, the downturn of marijuana stocks preceded the recent decline of the overall markets, as various public cannabis companies had a tough time meeting investors' lofty expectations.In yesterday's trading, Canopy Growth (NYSE:CGC) was, at one point, off 10.5% to $28.60 (the stock was over $50 a few months ago). That was after the stock had dropped 6.6% the day before. And on Wednesday, Tilray (NASDAQ:TLRY) dove 15%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe declines were kind of scary. But when it comes to investing, going against the grain can mean getting strong returns.One marijuana stock that should get attention is Hexo (NYSE:HEXO). Since late April, Hexo stock price has gone from $8.30 to $4.47.But HEXO has a number of positive characteristics. First of all, HEXO has gotten validation from Molson Coors (NYSE:TAP), which has formed a partnership with the cannabis company. The focus of the deal is developing a line of cannabis-infused beverages that will hit the market on Dec. 16th ( when such drinks will be legalized in Canada).All in all, the deal should provide Hexo stock with a nice catalyst. TAP will leverage its extensive marketing and logistical capabilities on behalf of HEXO's products. TAP's creative skills should help HEXO develop compelling products. The partnership really does look like a win-win.This is what the CEO of Molson Coors of Canada, Frederic Landtmeters, had to say about the deal: "We look forward to partnering with HEXO, a recognized leader in the medical cannabis space in Canada that will bring robust production capacity, a track record of innovation, and, most importantly, shared values when it comes to doing business the right way and earning the trust of consumers."But ultimately this is about more than just Canada. Because of the U.S. Farm bill, Hexo will be able to launch CBD-based drinks in eight states next year. Key AdvantagesThe TAP deal illustrates a main benefit of HEXO: the company's high production output. Note that it has about 30% of the Quebec market.Another critical factor is that HEXO acquired Newstrike Brands Ltd for $197 million. As a result of the deal, Hexo boosted its annual capacity by about 150,000 kilograms.Now it's true that Hexo stock is not without its issues. The company's last earnings report was a major disappointment. It revenue came in at 13.02 million CAD, representing a quarter-over-quarter drop of about 9%. while the Street was looking for $14.8 million.But the cannabis industry is still in the early stages, so choppy results are normal. Then again, the industry's fundamentals remain bright. That is why companies like TAP, Altria (NYSE:MO) and Constellation Brands (NYSE:STZ) have invested billions in the category. The Bottom Line on Hexo StockWhen it comes to the cannabis space, I think the key is to focus on the dominant players. Size will certainly be essential, given the competitive environment. And HEXO looks well-positioned to perform well over the long-haul.Yet the volatility of Hexo stock price will likely remain high. That is why it's a good idea to take moderate positions - or dollar-cost average - to help mute the wide swings of HEXO stock.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post Is Hexo Stock a Falling Knife Or Has It Reached a Good Entry Point? appeared first on InvestorPlace.

  • Juul's International Ambitions May Be the Real Value for Altria
    Motley Fool

    Juul's International Ambitions May Be the Real Value for Altria

    The tobacco giant has been dinged for its investment in the e-cig maker as concerns about U.S. regulation grow.


    New Cigarette Regulations Won’t Burn Big Tobacco, Analyst Says

    Altria, (PM) (PM), and their overseas peers are all preparing for a day when cigarettes aren’t their main products. Altria stock has fallen 7.6% year to date, as investors remain skeptical of its investments in vaping startup Juul Labs, the nicotine pouch product on!, and cannabis company Cronos Group (CRON). On Thursday, the FDA issued a new proposal that would introduce new graphic warnings on packs of cigarettes and advertisements to stress further the health risks of tobacco use and highlight lesser-known side effects.

  • 13 High-Yield Dividend Stocks to Watch

    13 High-Yield Dividend Stocks to Watch

    High-yield dividend stocks have gained even more allure lately in the face of shrinking bond yields. However, while a handful are ready buys right now, several more sport alluring yields - at least 5%, and up into the double digits - but need a little more time to simmer before it's time to dip in.Patience is a virtue in life. That's particularly true in the investing world. It's even true across investing disciplines. Sober value investors wait for their price before buying, but disciplined market technicians also know to wait for the proper setup before trading.Sometimes, you need to wait for a fundamental catalyst to make your trade worth making. Other times, it's simply a matter of waiting for the right price. But the key is having the self-control to wait for your moment. Lack of patience can be a portfolio killer."We tell our clients during the onboarding process that we won't be investing their entire portfolio on day one," explains Chase Robertson, Managing Partner of Houston-based RIA Robertson Wealth Management. "We tend to average into our portfolios over time as market conditions warrant, and we're not opposed to having large cash positions. Our clients thank us in the end."Today, we're going to look at 13 high-yield dividend stocks to keep on your watch list. All are stocks yielding over 5% that you probably could buy today, but all have their own unique quirks that might make it more prudent to watch them a little longer rather than jump in with both feet. SEE ALSO: 57 Dividend Stocks You Can Count On in 2019

  • Altria: What Will Drive Long-Term Growth?
    Market Realist

    Altria: What Will Drive Long-Term Growth?

    Altria (MO) stock has dipped roughly 5% so far in 2019, underperforming the broader market. MO stock is trading about 10% above its 52-week low price.

  • ACB Will Not Benefit From The Growth of Aurora Cannabis, Yet

    ACB Will Not Benefit From The Growth of Aurora Cannabis, Yet

    As marijuana stocks have struggled in recent months, much of the attention has revolved around Aurora Cannabis (NYSE:ACB). The company has made several key acquisitions to make itself the world's largest producer of dried marijuana. This should help ensure its future as competition forces the takeovers and bankruptcies of smaller players.Source: Shutterstock However, Aurora Cannabis is not Aurora Cannabis stock. The company's expansion has cost shareholders in share price declines and dilution of the equity. Until Aurora can fund growth through profit, investors should avoid ACB stock. Aurora Cannabis Should Remain a Top Canadian Marijuana CompanyAurora remains one of the more robust companies in this sector. As mentioned earlier, it leads in production, cultivating larger quantities of dried cannabis than even Canopy Growth (NYSE:CGC). Aurora Cannabis also operates in 25 countries.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDue to the oversupply of dried cannabis, it has rightly decided to turn its focus away from Canada and the U.S. The recent deal to provide 400 kilograms of medical marijuana to the Italian government pales in comparison to 25,000 kilograms of quarterly production. However, it constitutes a start to pare down the supply glut. * 15 Growth Stocks to Buy for the Long Haul Aurora gave investors a preview of the report to come as it issued fourth-quarter guidance. The company estimated quarterly production would come in between 25,000 and 30,000 kilograms. Analysts had expected 25,000 kilograms. Revenue guidance of between 100 million CAD ($75.15 million) and 107 million CAD fell short of the consensus 112 million CAD. Still, it represents massive growth from the 19.1 million CAD reported in the same quarter last year. Aurora's Growth Comes at the Expense of ACB StockHowever, what is suitable for a company may not benefit their stock. That seems especially true for Aurora Cannabis. I have long expressed concerns about high valuations. In a bull market, investors may tolerate high multiples in emerging sectors.However, the valuation faces pressure on more than one front. Turmoil related to the U.S.-China trade war and the protests in Hong Kong has brought the overall market down in recent days. With ACB stock trading at more than 53-times sales, both Aurora Cannabis and its high-value peers could face a steep drop on that factor alone.Analysts have also begun to notice. Piper Jaffray just initiated coverage. Despite speaking favorably about its "industry-leading capacity" and higher gross margins compared with its Canadian peers, it handed Aurora Cannabis with a "neutral" rating. It also thinks ACB stock trades at a premium compared to Canopy, Cronos Group (NASDAQ:CRON), and Tilray (NASDAQ:TLRY).Secondly, I have criticized Aurora Cannabis stock in past articles due to the massive dilution. There I cited the growth in shares outstanding from 129 million in 2016 to over one billion today.Our own Vince Martin believes the company will dilute Aurora Cannabis stock further. Barring a massive rise in the stock price, Aurora will have to pay back 230 million CAD ($172.9 million) of debt on March 9, 2020. ACB will likely have to issue more shares to pay this debt. As long as Aurora Cannabis stock bulls have to contend with significant amounts of dilution, they will find it difficult to profit from ACB. Final ThoughtsInvestors should avoid ACB stock until the company earns quarterly profits. Investors need to remain aware of the differences between Aurora Cannabis the company and its stock. With the number of shares growing by about eight-fold in three years, gaining traction with shares has become difficult.However, the dilution has benefitted Aurora Cannabis. The cash raised helped to fund 15 acquisitions, including the 3.2 billion CAD ($2.4 billion) MedReleaf deal. This has made Aurora a world leader in weed production and has given the company a presence in several countries.One day, after the hype around marijuana stocks has abated, I think ACB stock will become a profitable investment. Once it earns profits and pays dividends, it could even become the Altria (NYSE:MO) of weed. However, at this price level and under these conditions, investors should stay away from Aurora Cannabis.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post ACB Will Not Benefit From The Growth of Aurora Cannabis, Yet appeared first on InvestorPlace.

  • 1 Rock-Solid Marijuana Stock to Buy in a Recession
    Motley Fool

    1 Rock-Solid Marijuana Stock to Buy in a Recession

    This high-yield dividend stock should outperform during a market downturn.

  • Reuters

    UPDATE 3-U.S. FDA proposes graphic warnings on cigarette packs, advertisements

    The U.S. Food and Drug Administration has proposed that cigarette packs carry graphic new health warnings including pictures and text outlining lesser-known risks of smoking like bladder cancer and diabetes as well as lung cancer. The FDA said the proposed changes, which also drastically increase the size of the warnings, could be the most significant to cigarette labels in more than 35 years. The proposal also applies to cigarette advertisements, and would add 13 new warnings, along with colored pictures that outline the risk of diseases associated with smoking.


    Buy Philip Morris Stock Over Altria, but Prepare for a ‘Bumpy Ride’

    Buy Philip Morris stock over Altria, Bernstein says. But with plenty of uncertainty across the tobacco landscape, investors in these stocks may need to be ready for anything.

  • 3 Reasons to Love Cronos Stock

    3 Reasons to Love Cronos Stock

    The bumpy ride for Cronos (NASDAQ:CRON) stock investors continued this week when the cannabis stock got some more love from Wall Street. On Monday, Piper Jaffray analyst Micael Lavery initiated coverage of Cronos Group stock with an "outperform" rating and $18 price target.Lavery's initiation note was 29 pages long. However, the bull case for Cronos boils down to three main points.Source: ShutterstockInvestorPlace - Stock Market News, Stock Advice & Trading Tips CRON Stock Has a Big BrotherWhile other cannabis producers are out there trying to grow their business organically, Cronos has a perfect benefactor. In December 2018, tobacco giant Altria (NYSE:MO) invested $1.8 billion for a 45% stake in Cronos. In my opinion, the Altria partnership is the single biggest reason to consider CRON stock."We believe its partnership with Altria provides important capital ($1.8 billion cash) and access into 230,000 U.S. retail outlets, as well as regulatory and vapor product expertise," Lavery wrote. * 15 Growth Stocks to Buy for the Long Haul I would add two points to Lavery's case. U.S. (and potentially global) cigarette volumes are seemingly in secular decline. In other words, Altria needs Cronos as much as Cronos needs Altria. Tobacco companies are starving for growth. Cannabis could be a long-term lifeline.Second, Cronos Group stock investors hoping for U.S. cannabis legalization should realize one thing about their investment. They are investing in a tobacco company. As part of the terms of its 45% investment deal, Altria has the rights to take a full ownership stake at some point down the line.In my opinion, whether or not Altria exercises that option hinges on U.S. cannabis legalization. Without access to the U.S. market, Altria may not want to fully acquire Cronos. But if the U.S. ultimately legalizes weed on a federal level, I bet Altria's first move is a Cronos takeover.Progressive CRON stock investors may not like the idea of a tobacco takeover. But if the future of Altria is cannabis, at some point Altria is no longer a tobacco company at all. CBD Provides CRON Access to U.S. MarketAll cannabis stock investors know that U.S. federal marijuana legalization is the golden ticket. In the meantime, cannabidiol (CBD) may be the best way for Canadian producers like Cronos to get their foot in the U.S. door.CBD is a non-psychoactive, cannabis-derived chemical compound that was legalized in the U.S. in December 2018. The caveat is that only CBD produced from hemp, not marijuana, is legal. Lavery is expecting Cronos to use its $1.8 billion in Altria capital to launch a U.S. CBD strategy within the next year. In fact, he is projecting 60% of Cronos' 2020 revenue will come from CBD. Cronos Group's Brand AwarenessThe third big feather in Cronos Group's cap is its recent $300 million buyout of Redwood Holdings, parent company of early CBD brand leader Lord Jones.For millennial investors who are a fan of alternative data, Lavery included a cool statistic on Lord Jones in his note. Lord Jones alone has nearly 80,000 Instagram followers. That's more followers than the leading brands of popular cannabis stocks Tilray (NASDAQ:TLRY), Charlotte's Web Holdings (OTC:CWBHF) and Curaleaf Holdings (OTC:CURLF).It may seem like a trivial statistic, but social media popularity is an important measure of brand popularity. Marketing experts know brands are the key to success in untapped markets like the U.S. If Lord Jones becomes one of the gold standards in U.S. CBD, don't be surprised if Cronos/Altria markets its marijuana under the Lord Jones brand in the event of U.S. legalization. Understanding the Risks of CRON StockThe one thing I always try to include in my stories about cannabis stocks is a note about the risks involved in investing. There are so many uncertainties in the cannabis space right now. As if that weren't enough of a risk, cannabis stock valuations are sky-high, likely including at least some expected value from the U.S. marijuana market.Instead of rehashing points I've repeatedly made, here's Lavery's take:"We see a long runway of growth in the cannabis space, but valuation still has many speculative elements and can be very imprecise, given the early stages of the category and the myriad ways it could evolve," he wrote.Lavery makes some good points about buying CRON stock. However, any cannabis stock is a pure speculation at this time and these valuations. Don't invest any cash you wouldn't be comfortable losing in a worst-case scenario.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post 3 Reasons to Love Cronos Stock appeared first on InvestorPlace.

  • Tilray reports wider-than-expected 2Q losses, higher sales
    Yahoo Finance

    Tilray reports wider-than-expected 2Q losses, higher sales

    Canadian cannabis company Tilray reported second-quarter 2019 results after market close Tuesday.

  • 4 Big Dividend Stocks to Buy Now

    4 Big Dividend Stocks to Buy Now

    United States equities are catching a break Tuesday after President Donald Trump blinked and ordered the new 10% tariff on all remaining Chinese imports be delayed to December on certain high-profile items like cell phones and computer monitors. Yes folks, that means Apple (NASDAQ:AAPL) iPhone prices are safe -- for now.Ostensibly, this was done to ensure that measured inflation averages don't rise. This keeps the pressure on the Federal Reserve to consider further interest rate cuts to weaken the dollar and sends stocks higher. * 7 Safe Dividend Stocks for Investors to Buy Right Now That's resulting in a big relief bid in the market, bolstering a number of defensive high-dividend stocks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere are four worth a look right now: Dividend Stock to Buy: Philip Morris International (PM)Shares of Philip Morris International (NYSE:PM) were recently upgraded by Barclays analysts who are looking for a $100-per-share price target. While the company has been hurt by the rise of JUUL and other vaping competitors, it is responding with its own smoke-free products such as Marlboro's IQOS and HEETs. PM stock is enjoying a bounce off of its 50-day and 200-day moving averages.The company will next report results Oct. 17 before the bell. Analysts are looking for earnings of $1.37 per share on revenues of roughly $7.7 billion. When the company last reported July 18, earnings of $1.46 per share beat estimates by 13 cents on a 0.3% decline in revenues. The company pays a 5.5% dividend. Altria Group (MO)Altria Group (NYSE:MO) is the parent company of Philip Morris USA and Philip Morris International, the latter of which was spun off in 2008. That move freed Altria of Philip Morris USA's legal and regulatory constraints.MO stock is currently trading near the $46 per-share level, capping a long decline that started in early April. Altria stock has seen a roughly 18% loss from there. * 8 Dividend Aristocrat Stocks to Buy Now No Matter What MO stock pays a near 7% dividend yield. Shares were recently upgraded by Goldman Sachs analysts from neutral to buy, with a $59 price target assigned. The company will next report results Oct. 31 before the bell. Analysts are looking for earnings of $1.14 per share on revenues of $5.3 billion. When the company last reported on July 30, earnings of $1.10 per share matched estimates on a 6.4% rise in revenues. Las Vegas Sands (LVS)Shares of casino operator Las Vegas Sands (NYSE:LVS) are finding their legs near the stock's early June lows around $52, setting up a rally to challenge its 50-day and 200-day moving averages and possibly push LVS stock back towards prior highs in the mid-$60s. Such a move would be worth a gain of around 20% from here.The company will next report results Oct. 23 after the close. Analysts are looking for earnings of 77 cents per share on revenues of $3.3 billion. When the company last reported July 24, earnings of 72 cents per share missed estimates by 7 cents on a 0.9% rise in revenues. The company pays a 5.7% dividend yield. Ford Motor Company (F)Ford Motor Company (NYSE:F) shares are basing near their 200-day moving average, setting up a rally to retest prior highs near $10.25 on the expectation that further interest rate cuts will boost auto affordability and thus demand. The company pays a 6.5% dividend yield.Ford will next report results Oct. 23 after the close. Analysts are looking for earnings of 27 cents per share on revenues of $34.4 billion. When the company last reported July 24, earnings of 28 cents per share missed estimates by 3 cents on a 0.4% rise in revenues.As of this writing, William Roth did not hold any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Real Estate Investments to Ride Out the Current Storm * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk * 7 Safe Dividend Stocks for Investors to Buy Right Now The post 4 Big Dividend Stocks to Buy Now appeared first on InvestorPlace.

  • Benzinga

    Piper Jaffray Initiates Coverage Of Cronos, Says Stock 'Warrants A Premium Valuation'

    Cannabis stocks got a boost on Tuesday after a major Wall Street firm initiated bullish coverage of Cronos Group Inc (NASDAQ: CRON ). The Analyst Piper Jaffray analyst Michael Lavery initiated coverage ...

  • Tilray Stock Is Looking for a Turnaround

    Tilray Stock Is Looking for a Turnaround

    Shares of Tilray (NASDAQ:TLRY) stock will be in focus on Wednesday, after the company reports its quarterly results on Tuesday after the close. With cannabis stocks in focus lately, a strong quarter would go a long way to helping reverse the price action in TLRY stock and potentially turning the group around.Source: Shutterstock Cannabis stocks tend to be volatile, as there are a lot of considerations in play. There's the M&A factor to consider, as large companies plunk down lots of cash to get involved in cannabis. Take Constellation Brands (NYSE:STZ) investing $4 billion in Canopy Growth (NYSE:CGC) (which reports later this week) or Altria (NYSE:MO) dumping $1.8 billion in Cronos Group (NASDAQ:CRON).There are also regulatory wins and worries to consider, as part of the bullish thesis lies with various governments becoming more open-minded to the benefits of cannabis. There's also the fact that while many of these names boast incredible revenue growth, they also carry huge valuation risks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAdd it all together and you get a volatile group of up-and-coming growth stocks. Tilray's QuarterAnalysts expect Tilray to lose 25 cents per share this quarter, responsible for roughly one-quarter of the full-year loss of 99 cents per share they are forecasting for 2019. However, so long as the cash burn isn't too high and the losses are not too wide, the bottom line is not the focus at the moment. * 7 Safe Dividend Stocks for Investors to Buy Right Now Instead, the focus is sales. In that respect, analysts have some incredible forecasts. They expect revenue to jump ~322% this quarter to $41.1 million. That's slightly higher growth than their full-year forecasts for 308% growth, with estimates calling for $176.1 million in 2019 sales.The question is, what will it take for it to matter? Should TLRY beat on both earnings and revenue, will it be enough to entice investors?If the climate of the market turns more bullish, rather than remaining fearful, a beat could fuel Tilray higher. If the markets return to a risk-off approach in the next few weeks or months though, TLRY, CGC, and other cannabis players may find their stocks out of favor with investors.Remember, this is a stock that trades with a market cap value of $4.3 billion. At $176 million in sales, we're talking about 24 times this year's revenue. The entity doesn't turn a profit, and while the growth rate is still strong, that's a big valuation. Expectations call for another 103% growth in fiscal 2020, but you can see why there may be some concern.Before we do anything, we have to see the quarter from TLRY. Perhaps more importantly though, we have to see how the stock reacts to the quarter, which will tell us where investors stand on the name.To do that, let's look at the charts. Trading TLRY Stock Click to Enlarge Tilray stock has been in a painful downtrend since erupting higher in Q3 2018. Since then, a series of lower highs has continued to squeeze the stock lower and lower (purple line). However, that mood changed in June.Shares bottomed near $34.25, chopping near that mark for several consecutive sessions. TLRY then went on to reclaim its 20-day and 50-day moving averages, pushing through downtrend resistance in the process. It hasn't been completely smooth sailing during that time, with shares falling along that prior resistance level until hitting the $39 area. The good news though? Prior resistance is now acting as support, while the stock registered a higher low (blue line). That allows us to put in a short-term uptrend line.TLRY stock is not completely out of the woods here, but its chart is looking more constructive.Should we get positive Tilray news from its quarterly results, see that shares stay north of the 20-day and 50-day moving averages. With any luck, TLRY can reclaim the $47 to $50 area, and possibly begin a march back to its 200-day moving currently near $67.If the reaction is negative, I would love to see uptrend support hold. However, one "must-hold" spot for me is $39.31, to keep the trend of higher lows in play. If that fails, bulls need to make sure Tilray stock doesn't fall back below prior downtrend support.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Real Estate Investments to Ride Out the Current Storm * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk * 7 Safe Dividend Stocks for Investors to Buy Right Now The post Tilray Stock Is Looking for a Turnaround appeared first on InvestorPlace.

  • Narrative-Driven Cronos Group Stock Finally Has Good News

    Narrative-Driven Cronos Group Stock Finally Has Good News

    Although it is one of the most exciting sectors in the markets today, marijuana just can't catch a break. That sentiment extends to major players like Cronos Group (NASDAQ:CRON). Since March of this year, CRON stock has been fighting against a decidedly bearish trend channel. Seemingly with no bullish narrative on the horizon, weed investors just keep losing.Source: Shutterstock But what is driving the losses toward Cronos Group stock and its peers? No matter how you look at it, CRON has suffered from poor timing as bad news wracked the sector. Last month, Canadian cannabis firm CannTrust (NYSE:CTST) admitted that it had grown cannabis illegally in its facilities. The admission came after a Health Canada investigation.Even worse, the unlawful operation involved incredibly coordinated efforts. For instance, a CannTrust whistleblower reported that the company used fake walls to conceal the illegally grown cannabis. Initially, such tactics fooled Health Canada into believing everything was on the up and up.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks Under $7 to Invest in Now But what do CannTrust's controversies have to do with CRON stock? The answer is both nothing and everything. At first glance, it seems almost unfair for the markets to penalize Cronos Group stock. Both people and corporations should be judged on their actions, not on their perception of such.However, as we all know, marijuana is a narrative-driven market. And when a New York Stock Exchange weed ticker sparks a scandal on this magnitude, it's impossible the downfall won't impact CRON stock.Adding to the woes is that Cronos, like other marijuana companies, produced half-baked performances in the recent earnings season. Combining the available evidence, Cronos Group stock simply looks like a loser. Narrative Angle a Double-Edged Sword for CRON StockWhile I truly believe that legal marijuana offers a paradigm-shifting opportunity for investors, it has unique vulnerabilities. As I mentioned above, this sector is narrative-driven. Bad news, even unrelated to your target equity, can impose a severe impact.Under this context, the second-quarter earnings report for CRON stock didn't help. Although the company produced impressive headline numbers, accounting for non-recurring benefits, it was a rather disappointing showing. When you consider that market observers were hoping that at least one of the cannabis players would drive home a fundamentally substantive report, it's understandable why the sector sank.Although it's easy to get down on Cronos Group stock because it's so sensitive to news items, we should remember this point: a strong narrative should likewise deliver robust results in the markets.Right now, I believe Wall Street is downplaying the potential of Cronos' recent acquisition of Redwood Holdings. An American hemp and cannabidiol (CBD) company specializing in beauty products, Redwood gives CRON stock a firmer foothold in the U.S. cannabis market.Also, it allows Cronos to expand Redwood's footprint while everyone waits for the U.S. to emerge from the Stone Age. As you likely know, marijuana remains a Schedule I drug. Therefore, we have a clash between federal regulations and individual state laws.However, hemp-derived CBD is federally legal. That's because the 2018 farm bill changed the federal definition of hemp. Thus, Cronos via its Redwood acquisition has a viable pathway to American CBD consumers.That is a very big deal. According to a recent cannabis research paper, CBD sales in the U.S. could surpass $20 billion by 2024. With such an opportunity, you can see why Altria Group (NYSE:MO) invested nearly $2 billion into CRON stock. American CBD Will Save Cronos Group StockOf course, I completely understand why many people are hesitant to approach CRON stock. Most of my bullish arguments revolve around legal marijuana's potential. But in the here and now, this sector is largely a disappointment.But that's the beauty of weed, isn't it? If we were trading on known factors, this market wouldn't be so volatile. And if we truly knew with reasonable confidence this sector's upper boundaries, very few would invest. Simply put, the financials don't justify the risk.However, those upper boundaries are technically unknowns. That said, I believe that the probabilities support further integration of CBD into the U.S. market, not less. For instance, public support has reversed to the positive for marijuana legalization. Also, some studies indicate that CBD consumers are older, more educated, and are typically gainfully employed.With CRON stock and similar investments, we ultimately have two choices: We can look at the current state of affairs, which admittedly is unfavorable. Or, we can gamble that the U.S. market will continue to open doors, both legally and commercially. But there's a big gap between those two arguments, which explains this sector's volatility.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Sell Right Now * 7 Stocks Under $7 to Invest in Now * 7 Marijuana Stocks With Critical Levels to Watch The post Narrative-Driven Cronos Group Stock Finally Has Good News appeared first on InvestorPlace.

  • Why These Dividend-Paying Consumer Stocks Look Attractive
    Market Realist

    Why These Dividend-Paying Consumer Stocks Look Attractive

    As the broader markets take a hit, dividend-paying consumer stocks seem like a safe bet due to the sector's defensive nature.

  • ETFs in Focus as Consolidation Drives Marijuana Industry

    ETFs in Focus as Consolidation Drives Marijuana Industry

    Deals activity has been robust in the marijuana space, paving way for gains in these cannabis ETFs.

  • Can Tilray’s Q2 Earnings Revive TLRY Stock?

    Can Tilray’s Q2 Earnings Revive TLRY Stock?

    Tilray (NASDAQ:TLRY) stock has certainly lost its mojo. After a splashy IPO last year, it has been a downward grind for TLRY. In 2019, Tilray stock is off about 40%. To put this performance into perspective, consider that Cronos Group (NASDAQ:CRON) is up 29% and Canopy Growth (NYSE:CGC) has gained 22%.Regardless of all this, could TLRY get back into gear soon? Is the sentiment towards it too negative?Well, tomorrow after the market closes, when TLRY reports its second-quarter results, we should get a great deal of Tilray news and some answers to the questions posed above.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks Under $7 to Invest in Now Analysts, on average, expect Tilray's revenues to come to $41.11 million, up from $9.7 million in the same period a year earlier. Analysts' average estimate for Tilray's bottom line is a loss of 25 cents a share.In Q1 its revenue soared by 195.1% to $23 million and its loss came in at 32 cents a share. So TLRY is certainly doing a pretty good job of riding the cannabis wave. Q2 HighlightsIn Q2, there has been quite a bit of Tilray news. Here's a look at some of the highlights: * Tilray's Portugal subsidiary signed an agreement with Esporao, which will give TLRY 20 hectares of outdoor cultivation space in Alentejo, Portugal. This is part of the company's aggressive push to expand its opportunity in Europe. * The company announced that it would export a large amount of medical cannabis oral solutions from its Canadian factory to the United Kingdom. * TLRY signed a non-binding Letter of Intent with Privateer Holdings, which is the company's largest shareholder. It allows for an extension of the lock-up on 75 million shares of Tilray stock -- which represent 77% of those outstanding -- as well as the orderly selling of those shares. * Tilray announced that it obtained approval from the U.S. government for two clinical trials that will test the efficacy of cannabidiol, or CBD.The trials will focus on the efficacy of CBD for treating alcohol-use disorder (AUD) and post-traumatic stress disorder (PTSD). No doubt, the markets for AUD and PTSD are large. More than 15 million suffer from AUD and more than 8 million have PTSD in the U.S. According to Dr. Bogenschutz of NYU School of Medicine, where the trials will be conducted:"Our study is the first to investigate the effects of CBD in the treatment of alcohol use disorder, and will provide important new information on its mechanisms of action and clinical benefits." The Bottom Line on TLRYGauging the earnings of a company like TLRY is certainly difficult. After all, the cannabis industry is still in the early phases. There are also wildcards like supply-chain problems in Canada as well as black-market activities. But despite all this, the growth of the cannabis sector in general and TLRY in particular should remain strong.Yet expect Tilray stock to continue to be volatile. In other words,investors should be cautious about companies like Tilray. It's also important to keep in mind that some nagging issues are affecting Tilray's core business. For example, the company's production is relatively small, as its Q1 sales came in at 3,012 kilograms. By comparison, CGC sold over 10,000 kilograms in Q1.Finally, while other cannabis companies have snagged large investments from huge companies like Constellation Brands (NYSE:STZ) and Altria Group (NYSE:MO), Tilray has not yet attracted such a strategic investment. That is likely to hamper its progress, as size is critical for success in the cannabis industry. A strategic investor brings not just capital but also enhanced distribution capabilities, marketing acumen and product synergies. Investors who are interested in marijuana stocks should keep an eye on Tilray stock to see if the company can attract a large strategic investment.But for now, there are probably better options for capitalizing on the market, such as CGC or CRON.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Sell Right Now * 7 Stocks Under $7 to Invest in Now * 7 Marijuana Stocks With Critical Levels to Watch The post Can Tilray's Q2 Earnings Revive TLRY Stock? appeared first on InvestorPlace.

  • A $3 Opportunity in Aurora Cannabis Stock

    A $3 Opportunity in Aurora Cannabis Stock

    There could be a $3 rally brewing in Aurora Cannabis (NYSE:ACB) soon. The setup for this is almost perfect but it will take intestinal fortitude to hold ACB stock during this uncertainty on Wall Street.This morning we are seeing video of skirmishes in Hong Kong that could make the problems with China more acute. So the short term prognosis for stocks is guarded. Long term however, the thesis remains bullish behind central banks still geared for growth.The thesis for pot stocks has not changed much. So what captured everyone's imagination last year when they were rallying to the moon is still there. But with the advent of other distractions like IPOs, the novelty of cannabis stocks waned including ACB stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe perception is that Canopy Growth (NYSE:CGC) is the cream of the crop but Aurora stock price has performed better so far and for a while. So I see no particular reason why I should not bet on ACB here. Why Aurora Cannabis Stock Looks GoodThe opportunity here is a blend of technicals with fundamental backing. The charts reveal clues about what the investors plan to do with Aurora cannabis stock. Besides, the Tilray (NASDAQ:TLRY) earnings report this week should also create fireworks in Aurora stock. * 7 Stocks Under $7 to Invest in Now Late in 2017, ACB stock stepped up its game. It went from trading below $5 to a giant spike that took it to the all-time highs of $12 per share. Since then, it has made two complete round trips from highs to the $5 zone.But in March of this year, ACB stock topped out at $10 per share. This was a long-term lower-high trend but one that also has a well-defined bottom range above $5 per share.Below $6 per share, Aurora seems to find footing. This is where the bulls like to remount their buying efforts. So if we assume now that the stock markets in general are not collapsing, then it is safe to also assume that ACB stock buyers will make another effort to push prices towards the highs once more.There will be strong resistance at $7, $8 and $9 per share. These are zones, so think of them as rubber bands and not hard lines in the sand. The most significant level is $9, because it happens to be the point-of-control for over a year. This is where bulls and bears most agree on price based on the volume profile of ACB chart.This is an opportunity that is a speculative short-term bet on Aurora Cannabis. But if someone is looking to get into the pot stock investment for the longer-term, this can also double as a good starting point for that. Looking at Marijuana StocksThe bloom is off the rose for marijuana stocks, so to speak, this year. But that doesn't mean that the thesis for the stocks is dead. In fact nothing has changed from that perspective except the eagerness of Wall Street to buy stocks like Aurora Cannabis, CGC, Cronos (NYSE:CRON) and Tilray.Fundamentally, ACB stock, just like all of its competitors, is way too expensive from the traditional valuation perspective. But the story here is anything but traditional. These are intrepid companies trying to establish an industry that has not yet existed legally. So the road is tough and the investors must have a high tolerance for risk.Luckily the price tag for Aurora Cannabis offers a relatively low-dollar-risk attempt at profiting from the pot industry. The U.S. has yet to legalize the substance on the federal level. And when that happens it will be a game-changer for the stock prices.While the mania for the ACB stock price is gone, the fans of the story are still passionate. This makes for easier entry points, since the craziness of the bids has definitely subsided. We are far removed from the day when TLRY spiked to $300 per share on a massive short squeeze.So the buyers now have more conviction than they did just a few months ago, thereby making the investors now stronger hands holding ACB stock. At $6 per share, the long-term upside potential from here seems bigger than the downside danger.It is also important to note that we still have a ton of geopolitical risks -- most recently, the unrest in Hong Kong. And that's without mentioning the economic war between the U.S. and China.So buying any stock right now is risky enough, let alone a speculative one like Aurora Cannabis. So I don't enter full positions all at once so I would have room to manage my risk and add to it in the future.Nicolas Chahine is the managing director of As of this writing, he did not hold a position in any of the aforementioned securities. Join his live chat room free here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Sell Right Now * 7 Stocks Under $7 to Invest in Now * 7 Marijuana Stocks With Critical Levels to Watch The post A $3 Opportunity in Aurora Cannabis Stock appeared first on InvestorPlace.

  • 7 S&P 500 Dividend Stocks to Buy With Yields of at Least  3%

    7 S&P 500 Dividend Stocks to Buy With Yields of at Least 3%

    [Editor's note: "7 S&P 500 Dividend Stocks to Buy With Yields of at Least 3%" was previously published in June 2019. It has since been updated to include the most relevant information available.]In June, I read an article about Target (NYSE:TGT) that couldn't stop talking about the discount retailer's healthy dividend yield, which was yielding 3.15% as of Friday's close. While anything above 3% certainly can't be ignored, it turns out that 134 S&P 500 stocks currently offer a dividend yield of 3% or higher. So, the 3% yield isn't nearly as unique as many investors believe. For some investors, that means it might be smarter to consider ETFs that focus on dividend yields as part of their stock-selection process. InvestorPlace - Stock Market News, Stock Advice & Trading TipsThere are two high-dividend ETFs that focus on the S&P 500. The first is the Investco S&P 500 High Dividend Low Volatility ETF (NYSEARCA:SPHD). It focuses on the 50 S&P 500 stocks that historically have provided high dividend yields and low volatility. The second is the SPDR Portfolio S&P 500 High Dividend ETF (NYSEARCA:SPYD), which owns 80 high dividend-yielding S&P 500 stocks. Either of these could do the trick. * 7 Stocks Under $7 to Invest in Now However, this is an article about individual stocks to buy, so I'm going to pick at least three S&P 500 dividend stocks from each of the two ETFs that are currently yielding 3% or more. Ford (F)Source: Jens Mayer via Flickr (Modified)Ford (NYSE:F) was yielding 6.3% as of Friday's close, making it the 11th highest yielding S&P 500 stock. Ford's got too a great deal of upside potential, including a move into electric vehicles that should see a good chunk of its fleet electrified by the end of 2022. Yielding 6.3% and generating plenty of free cash flow, Ford stock is a great play for dividend investors. Altria (MO)Source: Peyri Herrera via Flickr (Modified)Altria (NYSE:MO) was yielding 6.9% as of Friday's close., making it the 6th highest yielding S&P 500 stock. In recent years, Altria's become known more for its acquisitions outside the cigarette industry, than anything it's done in its core business. On June 3, Altria announced that it was buying 80% of a Swiss smokeless tobacco company, whose smokeless oral pouch On is already sold in the U.S. Paying $372 million for Burger Sohne, it's adding another non-combustible product to the Altria portfolio. In the past year, Altria's paid almost $15 billion to buy a minority stake in e-cigarette maker Juul Labs and a 45% interest in Cronos Group (NASDAQ:CRON), one of Canada's largest cannabis companies. Altria's doing everything it can to ensure that when the cigarette industry dies its ultimate death, these new areas of business will more than compensate for the loss of sales in its legacy business. * 7 Stocks Under $7 to Invest in Now Altria's another reliable generator of free cash flow virtually ensuring the long-term payment of its $3.20 a year dividend. Kimco Realty (KIM)Source: Shutterstock The next of our stocks to buy, Kimco Realty (NYSE:KIM), was yielding 5.9% as of Friday's close., making it the 15th highest yielding S&P 500 stock. One of the oldest REITs in the U.S., it owns more than 400 shopping centers across the country, providing more than 61 million square feet for potential tenants.For those who might be worried about a REIT involved in the retail industry, Kimco's made sure to get tenants that are changing with the times. Not to mention its shopping centers are located in major metro markets, with 77% of its revenue coming from grocery-anchored malls. In addition, Kimco does a good job diversifying its tenants. It currently has 7,900 leases with 3,700 tenants with the top 12 tenants generating just 22% of its annualized base rent (ABR). The area where investors should focus on is the work Kimco's doing to redevelop some of its malls and shopping centers. In 2021 and beyond, it expects to invest up to $250 million annually to add additional retail and mixed-use redevelopments to existing properties. As the markets begin to lose their luster, stocks like KIM will deliver nice dividends for its shareholders even if the capital appreciation isn't always there. Target (TGT)Source: Mike Mozart via Flickr (Modified)Target was yielding 3.15% as of Friday's close, making it the 124th highest yielding S&P 500 stock. Barely making it on to the list, I picked Target's stock because it appears to be on a bit of a roll in 2019. The discount retailer's latest quarterly results were better-than-expected beating revenue estimates by $140 million and earnings by nine cents a share. However, it was the retailer's same-store sales growth (+4.8%) and online revenue growth (+42%) that really stood out for investors. Not only did online sales grow by 42% in the quarter, they now account for 7.1% of Target's overall sales, 190 basis points higher than a year earlier. To be truly omnichannel, it's got to get to double digits, something I expect it will do by the end of the fiscal year. As a result of its Q1 2019 results, CEO Brian Cornell suggested that Target is "well positioned to deliver strong financial performance in 2019 and beyond."Target expects to earn $5.90 a share in 2019 with same-store sales growth in the low- to mid-single-digits. * 7 Stocks Under $7 to Invest in Now The investments the company has made in its stores, e-commerce, and supply chain are starting to pay off. As long as the economy remains strong, Target stock could see $100 by the end of the year, making it a prime stock to buy. Public Storage (PSA)Source: Mike Mozart Via FlickrPublic Storage (NYSE:PSA) was yielding 3.13% as of Friday's close. As the tariff wars continue to heat up, investors continue to seek out investments that aren't going to be affected by tariffs on imported Chinese and Mexican goods. One area that stands out as a safe haven is the self-storage industry, an industry that benefits from America's love affair with junk. Public Storage's business has always been an attractive one because it's part self-storage facility and part real estate investment. PSA has 2,444 self-storage facilities in 38 states amounting to 164 million square feet of rentable space. It also owns 35% of European self-storage leader Shurgard, which owns 231 facilities offering 13 million square feet of rentable space. If you look at its balance sheet from the quarter ended March 31, you'll see that Public Storage's real estate is valued on its books at $9.3 billion excluding accumulated depreciation. That's just 1.6% higher than a year earlier. There's a reason for that. The numbers on the balance sheet reflect the cost of the land and its buildings, not the market value they'd generate if they were sold. As the parking lot business, self-storage facilities are a great way to generate income from the real estate until the value becomes such that it's worth more to a developer for apartments, offices, and mixed-use facilities. To be paid 3.13% to wait for the real estate to mature is an outstanding deal. Coty (COTY)Source: Shutterstock Coty (NYSE:COTY) was yielding 4.9% as of Friday's close. The company is in the early stages of a turnaround that began by moving Pierre Laubies into the CEO job in November 2018, followed by the hiring of a new CFO in January 2019. The two executives will lead a conference call on July 1 that will cover the critical components of their turnaround plan. As part of the plan, Coty will look to simplify its business to reduce the supply chain problems it's experienced in the past year. Although revenues and earnings are down in 2019, Coty managed to generate free cash flow of $120.5 million in the first nine months of fiscal 2019, a considerable turnaround from the negative free cash flow of $129.8 million in the first nine months of 2018. * 7 Stocks Under $7 to Invest in Now Slowly, the business is improving and aCoty stock, up 58% in 2019, reflects that. Despite the upturn, COTY is still a stock to buy. General Mills (GIS)Source: Shutterstock General Mills (NYSE:GIS) was yielding 3.6% as of Friday's close. making it the 76th highest yielding S&P 500 stock. General Mills, like many large packaged foods companies, has suffered in recent years from a move to more healthy alternatives. And while most of the big players have tried to adapt to the new order, they've got a ways to go before they're back on top. At General Mills, it took CEO Jeff Harmening's promotion to the top job in June 2017 to get the ball rolling. But even he'll admit the transformation isn't nearly done. "What I'm most proud of is… the change in culture… We've brought in a lot of people from outside of the organization who have added a lot of value in things like strategic revenue management and global sourcing and ecommerce, and a new chief marketing officer [Ivan Pollard, who came from Coca-Cola North America in July 2017, and is building a global marketing/media planning structure]. And we've blended [them] with our internal talent," Harmening stated recently in an interview. General Mills continues to invest in its e-commerce business, which could represent as much as 10% of its sales within five years. As for acquisitions, its multi-billion purchase of Blue Buffalo pet foods has been a hit with both e-commerce and the mass retail channels. As it continues to transform its business, shareholders should see GIS stock move even higher. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding The post 7 S&P 500 Dividend Stocks to Buy With Yields of at Least 3% appeared first on InvestorPlace.